Literature DB >> 3303928

Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Effect of successful tumor resection on mineral homeostasis.

I R Reid, S L Teitelbaum, A Dusso, M P Whyte.   

Abstract

Described herein is a case of oncogenic osteomalacia that ran a course of at least 16 years before curative resection of a mixed mesenchymal tumor. Hypercalcemic hyperparathyroidism developed in the patient, and review of the literature indicated that this occurs in about 10 percent of reported cases. Changes in serum parathyroid hormone levels with and without phosphate supplement therapy and before and after tumor resection suggested that both the high intake of phosphate and the effect of the neoplasm on vitamin D bioactivation engendered the parathyroid overactivity. Despite marked hyperparathyroidism, serum 1,25-dihydroxyvitamin D levels were subnormal preoperatively but showed a sevenfold increase within 48 hours of tumor resection. Thereafter, a gradual increase in the maximal tubular reabsorption of phosphate occurred during several months. Biopsy of the iliac crest confirmed that tumor removal was followed by resolution of osteomalacia, but there was no accompanying increase in vertebral mineral density as assessed by quantitative computed tomography or in total-body bone mineral as measured with dual-photon absorptiometry. The findings presented are consistent with secretion by the tumor of a factor with a short half-life that is potent enough to inhibit renal 25-hydroxyvitamin D-1 alpha-hydroxylase despite hyperparathyroidism. The resulting subnormal circulating 1,25-dihydroxyvitamin D levels may have secondarily contributed to decreased renal tubular reabsorption of phosphate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3303928     DOI: 10.1016/0002-9343(87)90711-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia.

Authors:  Q L Huang; D S Feig; M E Blackstein
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

2.  Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis.

Authors:  R S Weinstein; R L Harris
Journal:  Calcif Tissue Int       Date:  1990-06       Impact factor: 4.333

3.  Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia.

Authors:  Deng-Huang Su; Kuo-Meng Liao; Ying-Chun Chang; Keh-Sung Tsai
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis.

Authors:  Ksenya V Shelekhova; Dmitry V Kazakov; Ondrej Hes; Vladislav Treska; Michal Michal
Journal:  Virchows Arch       Date:  2006-01-31       Impact factor: 4.064

5.  Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report.

Authors:  I M Yang; Y K Park; Y J Hyun; D Y Kim; J T Woo; S W Kim; J W Kim; Y S Kim; Y K Choi
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

6.  Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.

Authors:  Kathryn Dahir; María Belén Zanchetta; Irinel Stanciu; Cemre Robinson; Janet Y Lee; Ruban Dhaliwal; Julia Charles; Roberto Civitelli; Mary Scott Roberts; Stan Krolczyk; Thomas Weber
Journal:  J Endocr Soc       Date:  2021-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.